tucatinib

Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
Motley Fool
Thu, 02/13/20 - 11:29 pm
Seattle Genetics
tucatinib
FDA
priority review
breast cancer
HER-2 postive breast cancer
SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data
Fierce Biotech
Wed, 12/11/19 - 10:27 am
Seattle Genetics
breast cancer
tucatinib
HER2+ breast cancer
SABCS
Here's Why Seattle Genetics Stock Jumped 25.7% in October
Motley Fool
Thu, 11/7/19 - 10:56 pm
Seattle Genetics
breast cancer
advanced breast cancer
clinical trials
tucatinib
Seattle Genetics' breast cancer drug hits mark in pivotal trial
Fierce Biotech
Mon, 10/21/19 - 10:03 am
Seattle Genetics
clinical trials
HER2+ breast cancer
tucatinib
Here's Why Seattle Genetics Climbed 17.6% in September
Motley Fool
Mon, 10/7/19 - 11:25 pm
Seattle Genetics
ESMO
clinical trials
tucatinib
colorectal cancer
enfortumab vedotin
urothelial cancer
Seattle Genetics makes case it can be more than Adcetris
Biopharma Dive
Mon, 09/30/19 - 12:03 pm
Seattle Genetics
Adcetris
clinical trials
ESMO
enfortumab vedotin
Astellas
tucatinib
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
CP Wire
Wed, 07/11/18 - 10:12 am
Seattle Genetics
tucatinib
orphan drugs
clinical trials
HER2-positive metastatic breast cancer
breast cancer
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
Wed, 07/11/18 - 09:37 am
Seattle Genetics
tucatinib
breast cancer
HER2-positive metastatic breast cancer
With new name, new CEO, Cascadian now rolls out a new pivotal plan for lead cancer drug
Endpoints
Wed, 12/7/16 - 10:16 am
Oncothyreon
Cascadian
tucatinib
ONT-380
treatment-resistant breast cancer
breast cancer